OmniAb, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. OmniAb develops antibody-discovery technologies and licenses its platform to pharmaceutical and biotechnology partners. The quarter’s results are standalone-company results; the comparable 2022 period reflects pre-separation combined results and may not be directly comparable.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $16.9 million | $9.6 million | +76% |
| Operating loss | $8.5 million | $8.2 million | Loss increased $0.2 million |
| Net loss | $6.1 million | $6.3 million | Loss decreased $0.2 million |
| Net loss per share, basic and diluted | $0.06 | $0.08 | Improved |
| Cash from operating activities | $27.7 million | $11.6 million | +$16.0 million |
- License and milestone revenue was $12.6 million, up 208%, primarily reflecting a $10 million milestone for the first EU commercial sale of teclistamab. Service revenue fell 25% to $4.0 million as activity declined on certain ion-channel programs. Royalties were $0.3 million.
- Operating expenses rose 42% to $25.4 million. R&D increased 28% to $13.8 million, principally due to personnel and facility costs; G&A nearly doubled to $8.2 million, primarily from personnel and public-company costs. The filing does not report gross profit or gross margin.
- Interest income was $1.3 million, compared with none in the prior period, reflecting interest earned on investments. Income tax benefit was $1.0 million versus $1.9 million; the reported effective tax rate was 14.4% in 2023.
- At March 31, cash and cash equivalents were $22.9 million and short-term investments were $90.7 million, totaling $113.6 million. Current assets were $121.1 million and current liabilities $21.7 million. No debt balance is reported in the presented balance sheet.
- Operating cash flow benefited substantially from a $28.8 million decrease in accounts receivable; accounts receivable fell from $30.3 million at year-end to $1.8 million. Investing cash outflow of $37.2 million mainly reflected purchases of short-term investments. Cash, cash equivalents and restricted cash ended at $23.3 million.
Material changes, outlook and risks
- Revenue growth was concentrated in a milestone payment, while service revenue declined. Net loss narrowed slightly despite higher operating expenses.
- Management believes cash, cash equivalents, short-term investments and expected operating cash generation will support operations for at least the next 12 months. No specific revenue or earnings guidance is provided.
- Management expects continued losses as it invests in R&D, platform commercialization, personnel and public-company infrastructure. Additional capital may be needed if cash flows or demand are below expectations; future financing may not be available on acceptable terms.
- Longer-term revenue depends on partners’ development, regulatory and commercialization decisions, which OmniAb does not control. The filing notes limited visibility into partners’ clinical progress. Management expects milestones to be more important in the near term and royalties potentially more significant over time, but timing and realization are uncertain.
- Potential unusual and noncash factors include the $10 million teclistamab milestone and $6.1 million of share-based compensation. Contingent liabilities were $6.2 million, including acquisition-related milestone obligations valued using significant unobservable assumptions. Operating lease liabilities totaled $25.9 million.
- Management reported no material change to previously disclosed risk factors, no material change in market risk, and effective disclosure controls as of March 31, 2023. Ordinary-course legal proceedings were not expected by management to have a material adverse impact, though outcomes remain uncertain.
Important facts for investors to verify
- Whether the $10 million milestone meaningfully overstates recurring revenue, and how milestone timing affects future quarterly comparisons.
- Cash generation excluding working-capital movements, especially the large accounts-receivable collection benefit this quarter.
- Partner-program progress and the potential for future milestones and royalties; the filing cites 70 active partners and 301 active programs, while its discussion gives differing active clinical program counts (24 in the overview and 27 in the metrics table).
- Cash runway under continued operating losses, and whether additional financing becomes necessary.
- Potential dilution from outstanding equity awards, earnout shares and warrants; the filing lists 57.7 million anti-dilutive or contingently issuable share equivalents.